Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENOIR: Phase 3 RSVpreF vaccine in adults ≥60 years
jRCT2051210096Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV) and respiratory syncytial virus lower respiratory tract infection comparing RSVpreF vaccine with Placebo (2 arms). Started Oct 2021; status: active, not recruiting.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)respiratory syncytial virus lower respiratory tract infection
Beyond the preview
Go deeper on jRCT2051210096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210096.